Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
MannKind is a biotechnology business based in the US. MannKind shares (MNKD) are listed on the NASDAQ and all prices are listed in US Dollars. MannKind employs 348 staff and has a trailing 12-month revenue of around $76.2 million.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $5.15 |
|---|---|
| 52-week range | $2.49 - $5.47 |
| 50-day moving average | $4.76 |
| 200-day moving average | $3.92 |
| Wall St. target price | $6.10 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.38 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.15 from 2023-01-30
| 1 week (2023-01-25) | -2.83% |
|---|---|
| 1 month (2022-12-30) | -2.28% |
| 3 months (2022-11-01) | 48.41% |
| 6 months (2022-08-01) | 43.85% |
| 1 year (2022-02-01) | 36.24% |
|---|---|
| 2 years (2021-02-01) | 41.10% |
| 3 years (2020-01-31) | 250.34% |
| 5 years (2018-02-01) | 97.32% |
| Revenue TTM | $76.2 million |
|---|---|
| Gross profit TTM | $36.6 million |
| Return on assets TTM | -20% |
| Return on equity TTM | 0% |
| Profit margin | -127.93% |
| Book value | $-0.90 |
| Market capitalisation | $1.4 billion |
TTM: trailing 12 months
We're not expecting MannKind to pay a dividend over the next 12 months.
MannKind's shares were split on a 1:5 basis on 2 March 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MannKind shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for MannKind shares which in turn could have impacted MannKind's share price.
Over the last 12 months, MannKind's shares have ranged in value from as little as $2.49 up to $5.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MannKind's is 1.6714. This would suggest that MannKind's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.